...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Outcomes of Patients With Coronary Arterial Bifurcation Narrowings Undergoing Provisional 1-Stent Treatment (from the BIONICS Trial)
【24h】

Outcomes of Patients With Coronary Arterial Bifurcation Narrowings Undergoing Provisional 1-Stent Treatment (from the BIONICS Trial)

机译：冠状动脉分叉狭窄患者的结果进行临时1支架治疗（来自仿生学试验）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Treatment of bifurcation lesions is technically challenging and has been associated with an increased risk of adverse events. We sought to evaluate the clinical and angiographic outcomes of patients who underwent bifurcation lesion provisional treatment in the BioNIR Ridaforolimus Eluting Coronary Stent System in Coronary Stenosis trial. A prospective, multicenter, 1:1 randomized trial was conducted to evaluate the safety and efficacy of ridaforolimus-eluting stents (RES) versus zotarolimus-eluting stents (ZES). Enrollment of bifurcation lesions treated with a provisional 1-stent technique was allowed. Bifurcation lesions were analyzed by an angiographic core laboratory. Outcomes were analyzed according to the presence of a bifurcation lesion treatment. Study population included 686 (35.8%) patients with and 1,228 (64.2%) patients without bifurcation lesion treatment. Procedural success was high and similar between groups. In 2 years, there was no difference in the rate of target lesion failure between the bifurcation and nonbifurcation groups (7.6% vs 7.3%, respectively, p = 0.81) regardless of the presence of side branch stenosis >= 50%. In 159 patients with angiographic follow-up, there was no difference in the rate of binary restenosis between groups (9.0% vs 9.2%, p = 0.96). Rates of target lesion failure at 1-year were similar with ZES and RES, and consistent in patients with and without bifurcation lesions (p(interaction) = 0.61). In conclusion, patients with bifurcation lesions treated and a provisional strategy experienced similar outcomes as those with nonbifurcation lesions. RES performed as well as ZES in bifurcation and nonbifurcation lesions. (C) 2020 Elsevier Inc. All rights reserved.
机译：分叉病变的治疗在技术上具有挑战性，并且与不良事件的风险增加有关。我们试图评估BioNIR Ridaforolimus洗脱冠状动脉支架系统在冠状动脉狭窄试验中接受分叉病变临时治疗的患者的临床和血管造影结果。进行了一项前瞻性、多中心、1:1随机试验，以评估利达福莫司洗脱支架（RES）与佐他莫司洗脱支架（ZES）的安全性和有效性。允许使用临时单支架技术治疗分叉病变。分叉病变由血管造影核心实验室进行分析。根据分叉病变的治疗结果进行分析。研究人群包括686名（35.8%）接受分叉病变治疗的患者和1228名（64.2%）未接受分叉病变治疗的患者。手术成功率高，组间相似。在2年内，分叉组和非分叉组的靶病变失败率没有差异（分别为7.6%和7.3%，p=0.81），无论是否存在侧支狭窄>=50%。在159名接受血管造影随访的患者中，两组之间的二元再狭窄率没有差异（9.0%对9.2%，p=0.96）。ZES和RES患者1年内的靶病变失败率相似，且在有和无分叉病变的患者中一致（p（交互作用）=0.61）。综上所述，分叉病变患者接受治疗并采取临时策略，其结果与非分叉病变患者相似。RES在分叉和非分叉病变中的表现与ZES相同。（C） 2020爱思唯尔公司版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号